Cassava Sciences settles SEC charges of ‘misleading’ Alzheimer’s trial claims

By / / Finance / 1 minute of reading



im 50326877
Shares of Cassava Sciences Inc. dropped more than 10% in the extended session Thursday after announcing a settlement with U.S. securities regulators, who had charged the pharma company and two former executives for “misleading claims” about an Alzheimer’s clinical trial.



Source link

About The Author

Avatar of Shana Hull
Shana Hull is a professional writer, editor, and interviewer. She's written for a variety of publications in the arts, construction, automotive, travel, real estate, and fashion industries. Shana has also worked as a content strategist for several companies in the finance and technology sectors.

Start typing and press enter to search

Scroll to Top